Lin BioScience, Inc. (TPEX: 6696)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
157.00
+2.50 (1.62%)
Nov 19, 2024, 2:59 PM CST
41.44%
Market Cap 12.15B
Revenue (ttm) n/a
Net Income (ttm) -731.66M
Shares Out 78.63M
EPS (ttm) -9.49
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 320,547
Open 156.00
Previous Close 154.50
Day's Range 153.50 - 158.50
52-Week Range 70.00 - 180.50
Beta -0.10
Analysts n/a
Price Target n/a
Earnings Date Nov 13, 2024

About Lin BioScience

Lin BioScience, Inc., a drug development company, develops therapies for oncology, ophthalmology, and metabolic diseases. Its product pipeline includes LBS-008, an oral therapy for dry age-related macular degeneration (Dry AMD)and stargardt diseases (STGD1), which is under Phase 3 clinical trial to evaluate safety and efficacy in adolescent STGD1 and under phase 2 or phase 3 clinical trial to evaluate safety and efficacy in Dry AMD; LBS-007, a natural non-ATP CDC7 inhibitor for the treatment of cancers; LBS-002, an anti-tubulin to treat primary... [Read more]

Industry Biotechnology
Sector Healthcare
CEO Zhengqi Wang
Country Taiwan
Stock Exchange Taipei Exchange
Ticker Symbol 6696
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.